ReNeuron partners with Fosun Pharma in China

ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market

ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales

09 April 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusive licence agreement (“the Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for the development, manufacture and commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in the People’s Republic of China (“China”).

Read more…

Clinical update and conference presentation

4 April 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a further update on progress with the ongoing Phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more…

Retinal clinical trial progresses to next stage

18 March 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a further update on progress with the ongoing Phase I/II clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more…

Positive preliminary data in US retinal trial

Significant improvement in vision in first cohort of Phase II subjects in US trial of hRPC cell therapy in retinitis pigmentosa

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more…

New exosome production scale-up data presented

31 January 2019 : ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes will be presented today at a leading US forum on the manufacture of cell and gene therapies.

Read more …

 

First patient treated in US stroke clinical trial

24 January 2018: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the first patient has been treated in the US Phase IIb clinical study of the Company’s CTX cell therapy candidate for stroke disability.

Read more…

ReNeuron signs exosome collaboration

4 January 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of the Company’s exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.

Read more…

 

 

Interim Results for the six months ended 30 September 2018

14 December 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2018.

Read more

To log on to view the webcast of the analyst presentation please click here…

To view the Interim Results Presentation slide deck please click here…

 

Notification of Interim Results

20 November 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2018 on Friday 14 December 2018.

Read more…

ReNeuron’s lead cell line shows further potential

New data shows ReNeuron’s lead CTX cell therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types

18 October 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Lausanne, Switzerland.

Read more…